PML-RARA (Promyelocytic Leukemia/Retinoic Acid Receptor Alpha) Translocation, t(15;17) Analysis
Acute myelogenous leukemia of Promyelocytic type (AML-M3, Acute Promyelocytic Leukemia) is a subtype of acute myelogenous leukemia. It is associated with characteristic pathologic and clinical features. One of the characteristic molecular pathologic features is the presence of a translocation between the retinoic acid receptor alpha gene on chromosome 17 with the acute promyelocytic leukemia (APL) gene on chromosome 15. This translocation is present in over 99% of APL patients and its presence is diagnostic of APL given the appropriate light microscopic and histochemical features.
Patients with APL respond to treatment with all-trans-retinoic acid, and the RARA/APL translocation is necessary for this response. Patients without this translocation who have other types of AML do not respond to all-trans-retinoic acid. Patients with APL have a high incidence of disseminated intravascular coagulation and mortality if they do not receive proper therapy; hence, diagnosis is crucial. The PML/RARA assay utilizes two molecular methods to detect the PML/RARA translocation: conventional cytogenetic detection of the t(15;17) translocation (FISH) assay and PML/RARA fusion transcript by reverse transcription-PCR (RT-PCR) assay. Detection of the PML/RARA fusion transcript by reverse transcription-PCR (RT-PCR) is more sensitive than conventional cytogenetic detection of the t(15;17) translocation and best predicts therapeutic response to all-trans-retinoic acid. The quantitative PCR assay is also useful for monitoring therapeutic response and detecting minimal residual or recurrent disease. Although APL can be diagnosed on the basis of morphology, presence of the t(15;17) translocation or PML/RARA gene expression is required for response to all-trans-retinoic acid as well as arsenic trioxide. The absence of this translocation excludes PML as a consideration.
- Differential diagnosis of AML-M3 (Acute promyelocytic leukemia)
- Therapy selection and assessment of efficacy.
- Monitoring the level of PML/RARA in PML patients.
- Differential diagnosis of other types of acute promyelocytic leukemia (APL)
- Monitor patients for APL recurrence
- Predicting therapeutic response to all-transretinoic acid and arsenic trioxide
- For suspected low-level recurrent or minimal residual disease (MRD) detection and monitoring
Both assays are read as either positive (PML/RARA translocation present) or negative (PML/RARA translocation absent). Some labs may use a normalized ratio to report results. This is the ratio of PML/RARA RNA present in the specimen compared to an internal control, often beta glucuronidase RNA. The ratio has no units but is directly proportional to the amount of PML/RARA RNA present. PML/RARA levels can be compared only if testing is done using the same methodology and preferably in the same lab.
Positive results with either assay indicate that the cells carry the PML/RARA t(15;17) translocation and are diagnostic for APL. Because the efficacy of all-trans-retinoic acid and arsenic trioxide has not been demonstrated in patients who lack the PML/RARA t(15;17) translocation, other forms of treatment should be considered for patients without evidence of this rearrangement.
In the PCR assay, the short isoform may be associated with shorter disease-free and overall survival. The analytical sensitivity of this test is 1 tumor cell in 100,000 normal cells.
PML/RARA translocation absent: AML-M3 (APL) is not present, or Negative for PML/RARA translocation.
Quantitative RT-PCR: Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) procedures detect the two types of PML/RAR-alpha fusion transcripts (long and short isoforms). In addition, the abl gene is also amplified and used as an internal control for sample RNA quality and for quantification (expression ratio). If the PML/RARA t(15;17) translocation is detected, the result is considered positive and the ratio between amplified PML/RARA fusion transcript and the internal control or ABL transcript is reported. If there is no PML/RARA amplification (ratio = 0), the result is reported as negative.
FISH Method: FISH, AML M3, PML/RARA, Translocation 15;17 is a fluorescence in situ hybridization (FISH) method that uses dual color probes to detect the PML and RARA loci. A PML/RARA fusion signal is in cells with the translocation is detected and reported if present. No translocation or amplification is detected in negative cases. In cases with negative cytogenetic results, a FISH assay may be performed on the same sample.
Whole Blood EDTA (Lavender), Heparin (Green) , ACD (Yellow) or Bone Marrow.
Stability
- Ambient: 1-3 days
- Refrigerated: 3-5 days
3-5 days.
- Hematology Am Soc Hematol Educ Program. 2008: 391-9. [PMID: 19074116]
- N Engl J Med. 1998;339(19): 1341-8. [PMID: 9801394]
- Acta Med Scand. 1957;159 (3): 189-94. [PMID: 13508085]
- Br J Haematol. 2003;122 (4): 563-70. [PMID: 12899711]
- EMBO J. 1993;12 (3): 1161-7. [PMID: 8384553]
- Blood. 2002;100 (7): 2292-302. [PMID: 12239137]